ClinicalTrials.gg
CompletedNCT07059858Updated Nov 2, 2026

Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities

An observational study in Intellectual Disability and Healthy Subjects, sponsored by Abant Izzet Baysal University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Abant Izzet Baysal University · Observational

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
102
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Intellectual Disability with a site in Turkey — 5 open to participants now, 8 under way, none of them phase 3. Intellectual Disability · Turkey.

Started
2025
with 9 others
Observational
5 of 29
1 open now
Registered
19th of 29
by date
Lead sponsor
1 of 29
Abant Izzet Baysal University

Among the 29 studies in Intellectual Disability with a site in Turkey, this one is one of 10 that started in 2025, is one of 5 observational ones, and was the 19th registered.

Intellectual Disability

389 studies on the registry are indexed under Intellectual Disability; 107 are open to participants now.

Browse Intellectual Disability studies →

Open to participants now

5 of the 29 studies in Intellectual Disability with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 69 Intellectual Disability studies recruiting now, 27 (39%) set no upper age limit and 33 (48%) stop at 75 or younger; 49 take children under 18; 13 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intellectual Disability with a site in Turkey, or all of them as a file.
02

Study summary

Many neurodevelopmental, psychiatric, and medical disorders are commonly associated with intellectual disability. The presence of neurodevelopmental and psychiatric (NDP) comorbidities has been reported to negatively impact the clinical outcomes of bowel or bladder dysfunction.

Pediatric bladder and bowel dysfunction (BBD) is a common but underdiagnosed condition characterized by a spectrum of lower urinary tract symptoms and is often associated with constipation. Lower urinary tract symptoms include dysuria, urinary urgency, daytime incontinence, and enuresis, while bowel symptoms include constipation and encopresis. Most BBD cases are functional and not neurogenic in origin.

In children with special needs, all types of urinary incontinence are reported to occur more frequently compared to children without developmental or behavioral disabilities. Intellectual disability (IQ \<70) is also identified as a significant risk factor for urinary incontinence, with prevalence increasing as IQ decreases. In these children, lower urinary tract symptoms such as overactive bladder, dysfunctional voiding, and low fluid intake are also observed. Furthermore, according to support plans and medical records, 94% of individuals with intellectual and multiple disabilities experience constipation. Interestingly, lower levels of intellectual disability (profound and severe ID) have been associated with a lower prevalence of constipation.

Although there are studies in the literature examining bladder and bowel functions separately in specific diagnostic groups with intellectual disability, the number of studies that assess bladder and bowel functions together in children with any form of intellectual disability is limited. Moreover, to our knowledge, there is no study in the literature that evaluates bladder and bowel functions along with child participation and parental quality of life in children with intellectual disability.

Based on this gap in the literature, the aim of our study is to examine bladder and bowel functions, participation, and quality of life in children with intellectual disability

Read the detailed description

This cross-sectional study will include children aged 5-12 years with intellectual disabilities who are attending Special Education and Rehabilitation Centers, as well as typically developing children. Necessary approvals will be obtained from the Non-Interventional Clinical Research Ethics Committee of Bolu Abant Izzet Baysal University.

Participants will be selected according to predefined inclusion criteria. Informed consent will be obtained from both the children included in the study and their parents. Sociodemographic data such as parents' age, height, weight, marital status, and education level will be recorded. Similarly, data on the children, including age, height, weight, and gender, will be collected.

Bladder and bowel functions of the children included in the study will be assessed using the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ), the Dysfunctional Voiding and Incontinence Scoring System (DVISS), and the Lower Urinary Tract Symptom Score (LUTSS). Child participation will be evaluated using the Child and Adolescent Scale of Participation (CASP). Parental quality of life will be assessed using the Nottingham Health Profile (NHP), and children's quality of life will be evaluated using the Pediatric Quality of Life Inventory - Gastrointestinal Symptoms Module (PedsQL GI Module)

03

Conditions studied

  • Intellectual Disability
  • Healthy Subjects
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Children diagnosed with intellectual disability and typically developing peers who agreed to participate in the study and met the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Children with Intellectual Disabilities:

  • Aged between 5 and 12 years
  • Diagnosed with mild, moderate, or severe intellectual disability as documented by the ÇÖZGER (Child Special Needs Report)
  • Both the parent and the child agree to participate in the study

For Typically Developing Children

  • Aged between 5 and 12 years
  • Both the parent and the child agree to participate in the study

Exclusion criteria

Exclusion Criteria:

For Children with Intellectual Disabilities:

  • Having a diagnosis of physical disability
  • Presence of a neurological anomaly affecting bladder and bowel functions
  • Parent does not consent to participate in the study
  • Having undergone trauma or surgery affecting bladder and bowel functions within the last 6 months
  • Diagnosis of a genetic disorder
  • Use of medications that may affect bladder and bowel functions

For Typically Developing Children

  • Presence of a neurological anomaly affecting bladder and bowel functions
  • Lack of parental consent to participate in the study
  • Having experienced trauma or undergone surgery affecting bladder and bowel functions within the past 6 months
  • Use of medications that may influence bladder and bowel functions
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
102 participants (actual)
Patient registry
No

Groups and cohorts

  • Intellectual Disability Group

    Individuals between the ages of 5-12 years with a diagnosis of intellectual disability

  • Typical Developing Group

    Typically developing individuals between the ages of 5-12

06

What researchers measure

Primary outcomes

  1. Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ

    The CBBDQ is a parent-reported instrument used to assess and quantitatively measure symptoms of bladder and bowel dysfunction in children. It is designed for children aged 5 to 12 years and consists of 18 items, including 10 items related to bladder symptoms and 8 items related to bowel symptoms. Each item is rated on a five-point Likert scale ranging from 0 (never) to 4 (almost every day or every day). Higher CBBDQ scores indicate the presence of more severe or frequent symptoms.

    Time frame: baseline

  2. Bladder and Bowel Dysfunction Scale (BBDS)

    The BBDS is a 14-item questionnaire designed to assess pediatric bladder and bowel dysfunction. Each item is rated using a five-point Likert scale. The total score ranges from 0 to 52, with higher scores indicating greater symptom severity. The scale includes 14 questions, of which the first 13 specifically address symptoms related to bladder and bowel dysfunction. The final question evaluates the level of difficulty experienced while completing the questionnaire and is not included in the total score.

    Time frame: baseline

  3. Voiding Dysfunction Symptom Score (VDSS)

    The Voiding Dysfunction Symptom Score (VDSS) was developed by Akbal et al. in 2005 and consists of 14 items. Thirteen of the items assess symptoms related to daytime urinary incontinence, nighttime urinary incontinence (enuresis), urinary frequency during the day, the presence of constipation, and various lower urinary tract symptoms. The 14th item evaluates the impact of these symptoms on quality of life. The total score ranges from 0 to 35 points, with higher scores indicating increased severity of voiding dysfunction symptoms. The overall score is considered to be 35+3, with the additional 3 points referring to the quality-of-life impact assessment.

    Time frame: baseline

  4. Child and Adolescent Scale of Participation (CASP)

    The Child and Adolescent Scale of Participation (CASP) is a caregiver-reported measure used to assess the extent to which school-aged children (aged 5 years and older) participate in home, school, and community activities compared to their same-age peers. The scale consists of 20 items grouped into four subdomains: Home Participation (6 items), Community Participation (4 items), School Participation (5 items), and Home and Community Living Activities (5 items). Each of the 20 items is rated on a four-point scale: "Age Expected (Full participation)," "Somewhat Limited," "Very Limited," and "Unable to Participate." If the item reflects an activity that is not age-appropriate for the child (e.g., employment), the response "Not Applicable" is selected. Higher scores indicate greater levels of participation. In addition, the CASP includes five open-ended questions that explore effective strategies and supports, as well as barriers that may influence the child's participation.

    Time frame: baseline

Secondary outcomes

  1. Pediatric Quality of Life Inventory - Gastrointestinal Symptoms Module (PedsQL GI Module)

    The PedsQL GI Module is designed for different age groups (2-4 years, 5-7 years, 8-12 years, and 13-18 years). It includes 74 items for both child self-report and parent proxy-report versions. The module consists of 10 separate Likert-type subscales that assess various gastrointestinal symptoms. Higher scores on the PedsQL GI Module indicate better health-related quality of life, while lower scores reflect a greater negative impact of gastrointestinal symptoms on quality of life.

    Time frame: baseline

  2. Nottingham Health Profile (NHP)

    The Nottingham Health Profile (NHP) is used to assess health-related quality of life. It is a general quality of life questionnaire that measures an individual's perceived health problems and the extent to which these problems affect normal daily activities. The questionnaire consists of 38 items and evaluates six dimensions of health status. The items are answered with a "yes" or "no" response. Each section is scored on a scale from 0 to 100, where a score of 0 indicates the best possible health status and a score of 100 indicates the worst. Within the scope of this study, both the subscale scores and the total NHP score will be evaluated. The total NHP score will be calculated as the sum of the subscale scores.

    Time frame: baseline

07

Study locations

1 site
  • Abant Izzet Baysal University Faculty of Health Science
    Bolu, 14100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Mar 2026, 5 months.

Of 47 non-industry observational studies under Intellectual Disability, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 203. This study's 5 months is below that.

Counting every sponsor, half of 48 studies reached it within 59 months; a quarter within 19 and three quarters within 203.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2026 → Mar 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 11, 2025
StartActual
Sep 28, 2025
Primary completionActual
Mar 2, 2026was Sep 2026
CompletionActual
Oct 2, 2026was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Sep 2, 2026→Mar 2, 2026 (actual)
Nov 2, 2026
Study completion
Dec 2, 2026→Oct 2, 2026 (actual)
Nov 2, 2026
Enrollment
100 (estimated)→102 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Sep 2, 2026→Mar 2, 2026 (now actual)
    Study completion Dec 2, 2026→Oct 2, 2026 (now actual)
    Enrollment 100 (estimated)→102 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07059858
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Sep 28, 2025
Primary completion
Mar 2, 2026
Completion
Oct 2, 2026
Last update
Nov 2, 2026

Study contacts

Sezen Tezcan, PhD
principal investigator · Abant Izzet Baysal University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion